Table 1 Population characteristics evaluated according to AAD incidence

Age (years; IQR)

4.9 (2.6–8.0)

3.5 (1.7–8.9)

Gender^a

 Male

360 (53)

36 (45)

Age groups^a

 1–24 months

122 (85.3)

21 (14.7)

 2–7 years

323 (91.2)

31 (8.8)

 7–12 years

170 (91.4)

13 (6.9)

  > 12 years

74 (85.1)

13 (14.9)

Geographic regions^a

 Eastern Anatolia

15 (75)

5 (25)

 Southeast Anatolia

136 (83.5)

27 (16.5)

 Mediterranean Region

30 (85.8)

5 (14.2)

 Central Anatolia

184 (90.4)

20 (9.6)

 Marmara Region

215 (93.2)

15 (6.8)

 Aegean Region

55 (93)

4 (7)

 Black Sea Region

42 (93.4)

3 (6.6)

Type of infection^a

 Acute tonsillopharyngitis

174 (87.4)

24 (12.1)

 Lower respiratory infection

112 (93.3)

8 (6.7)

 Acute otitis media

103 (85)

17 (15)

 Acute rhinosinusitis

105 (92.1)

9 (7.9)

 Soft tissue infection

45 (84.9)

8 (15.1)

 Urinary tract infection

45 (86.5)

7 (13.5)

 Acute lymphadenitis

78 (92.9)

6 (7.1)

 Others

17 (100)

-

Treatments and doses^a

 Aminopenicillins

  Amoxicillin/clavulanic acid (usual dose)^b

250 (91.6)

23 (8.4)

  Amoxicillin/clavulanic acid (high dose)^c

142 (87.7)

20 (12.3)

  Amoxicillin/clavulanic acid (max dose)^d

30 (83.3)

6 (16.7)

  Amoxicillin (high dose)^c

3 (100)

-

  Amoxicillin (usual dose)^b

8 (100)

-

  Ampicillin/sulbactam^b

4 (100)

-

 Cephalosporins

107 (85.6)

18 (14.4)

  Cefuroxime^e

28 (92.9)

2 (7.1)

  Cefdinir^f

43 (79.6)

11 (20.4)

  Cefixime^g

36 (87.8)

5 (12.2)

 Macrolides^h

64 (94)

4 (6)

 Phenoxymethyl penicillinⁱ

51 (89.5)

6 (10.5)

 Others

19 (92.4)

2 (7.6)